Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025691036> ?p ?o ?g. }
- W3025691036 endingPage "e2322" @default.
- W3025691036 startingPage "e2311" @default.
- W3025691036 abstract "Objective To evaluate the efficacy and safety of adjunctive cenobamate 200 mg/d in patients with uncontrolled focal (partial-onset) seizures despite treatment with 1 to 3 antiepileptic drugs. Methods In this multicenter, double-blind, placebo-controlled study, adults 18 to 65 years of age with focal seizures were randomized 1:1 (cenobamate:placebo) after an 8-week baseline period. The 12-week double-blind treatment period consisted of a 6-week titration phase and a 6-week maintenance phase. The primary outcome was percent change in seizure frequency (from baseline) per 28 days during double-blind treatment. Results Two hundred twenty-two patients were randomized; 113 received cenobamate and 109 received placebo; and 90.3% and 90.8% of patients, respectively, completed double-blind treatment. Median baseline seizure frequency was 6.5 in 28 days (range 0–237). Compared to placebo, cenobamate conferred a greater median percent seizure reduction (55.6% vs 21.5%; p < 0.0001) The responder rate (≥50% reduction in seizure frequency) was 50.4% for cenobamate and 22.2% for placebo ( p < 0.0001). Focal seizures with motor component, impaired awareness, and focal to bilateral tonic-clonic seizures were significantly reduced with cenobamate vs placebo. During maintenance, 28.3% of cenobamate-treated and 8.8% of placebo-treated patients were seizure-free. Treatment-emergent adverse events reported in >10% in either group (cenobamate vs placebo) were somnolence (22.1% vs 11.9%), dizziness (22.1% vs 16.5%), headache (12.4% vs 12.8%), nausea (11.5% vs 4.6%), and fatigue (10.6% vs 6.4%). Conclusion Adjunctive treatment with cenobamate 200 mg/d significantly improved seizure control in adults with uncontrolled focal seizures and was well tolerated. ClinicalTrials.gov identifier NCT01397968. Classification of evidence This study provides Class I evidence that, for patients with uncontrolled focal seizures, adjunctive cenobamate reduces seizures." @default.
- W3025691036 created "2020-05-21" @default.
- W3025691036 creator A5004620817 @default.
- W3025691036 creator A5025122018 @default.
- W3025691036 creator A5033661505 @default.
- W3025691036 creator A5038885649 @default.
- W3025691036 creator A5062520786 @default.
- W3025691036 creator A5064633149 @default.
- W3025691036 creator A5064704800 @default.
- W3025691036 creator A5071938770 @default.
- W3025691036 creator A5078868975 @default.
- W3025691036 creator A5086532171 @default.
- W3025691036 date "2020-05-14" @default.
- W3025691036 modified "2023-10-11" @default.
- W3025691036 title "Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures" @default.
- W3025691036 cites W1498758291 @default.
- W3025691036 cites W1524327358 @default.
- W3025691036 cites W1551373999 @default.
- W3025691036 cites W180654068 @default.
- W3025691036 cites W1857985470 @default.
- W3025691036 cites W1916788136 @default.
- W3025691036 cites W1974809694 @default.
- W3025691036 cites W1992028227 @default.
- W3025691036 cites W2005134750 @default.
- W3025691036 cites W2012369961 @default.
- W3025691036 cites W2016326495 @default.
- W3025691036 cites W2051013481 @default.
- W3025691036 cites W2058596886 @default.
- W3025691036 cites W2063476303 @default.
- W3025691036 cites W2067241131 @default.
- W3025691036 cites W2082045121 @default.
- W3025691036 cites W2090276138 @default.
- W3025691036 cites W2135808877 @default.
- W3025691036 cites W2145520222 @default.
- W3025691036 cites W2163886527 @default.
- W3025691036 cites W2168419043 @default.
- W3025691036 cites W2171583595 @default.
- W3025691036 cites W2203865877 @default.
- W3025691036 cites W2472978162 @default.
- W3025691036 cites W2592509339 @default.
- W3025691036 cites W2594644573 @default.
- W3025691036 cites W2601045941 @default.
- W3025691036 cites W2624406735 @default.
- W3025691036 cites W2777270043 @default.
- W3025691036 cites W2801123635 @default.
- W3025691036 cites W2899577938 @default.
- W3025691036 cites W2944392111 @default.
- W3025691036 cites W2960816639 @default.
- W3025691036 doi "https://doi.org/10.1212/wnl.0000000000009530" @default.
- W3025691036 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7357293" @default.
- W3025691036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32409485" @default.
- W3025691036 hasPublicationYear "2020" @default.
- W3025691036 type Work @default.
- W3025691036 sameAs 3025691036 @default.
- W3025691036 citedByCount "91" @default.
- W3025691036 countsByYear W30256910362020 @default.
- W3025691036 countsByYear W30256910362021 @default.
- W3025691036 countsByYear W30256910362022 @default.
- W3025691036 countsByYear W30256910362023 @default.
- W3025691036 crossrefType "journal-article" @default.
- W3025691036 hasAuthorship W3025691036A5004620817 @default.
- W3025691036 hasAuthorship W3025691036A5025122018 @default.
- W3025691036 hasAuthorship W3025691036A5033661505 @default.
- W3025691036 hasAuthorship W3025691036A5038885649 @default.
- W3025691036 hasAuthorship W3025691036A5062520786 @default.
- W3025691036 hasAuthorship W3025691036A5064633149 @default.
- W3025691036 hasAuthorship W3025691036A5064704800 @default.
- W3025691036 hasAuthorship W3025691036A5071938770 @default.
- W3025691036 hasAuthorship W3025691036A5078868975 @default.
- W3025691036 hasAuthorship W3025691036A5086532171 @default.
- W3025691036 hasBestOaLocation W30256910361 @default.
- W3025691036 hasConcept C118552586 @default.
- W3025691036 hasConcept C126322002 @default.
- W3025691036 hasConcept C142724271 @default.
- W3025691036 hasConcept C168563851 @default.
- W3025691036 hasConcept C197934379 @default.
- W3025691036 hasConcept C204787440 @default.
- W3025691036 hasConcept C27081682 @default.
- W3025691036 hasConcept C2778186239 @default.
- W3025691036 hasConcept C2779034229 @default.
- W3025691036 hasConcept C2780580376 @default.
- W3025691036 hasConcept C42219234 @default.
- W3025691036 hasConcept C71924100 @default.
- W3025691036 hasConceptScore W3025691036C118552586 @default.
- W3025691036 hasConceptScore W3025691036C126322002 @default.
- W3025691036 hasConceptScore W3025691036C142724271 @default.
- W3025691036 hasConceptScore W3025691036C168563851 @default.
- W3025691036 hasConceptScore W3025691036C197934379 @default.
- W3025691036 hasConceptScore W3025691036C204787440 @default.
- W3025691036 hasConceptScore W3025691036C27081682 @default.
- W3025691036 hasConceptScore W3025691036C2778186239 @default.
- W3025691036 hasConceptScore W3025691036C2779034229 @default.
- W3025691036 hasConceptScore W3025691036C2780580376 @default.
- W3025691036 hasConceptScore W3025691036C42219234 @default.
- W3025691036 hasConceptScore W3025691036C71924100 @default.
- W3025691036 hasIssue "22" @default.
- W3025691036 hasLocation W30256910361 @default.
- W3025691036 hasLocation W30256910362 @default.